Show simple item record

dc.contributor.authorHarvey, William T
dc.contributor.authorCarabelli, Alessandro
dc.contributor.authorJackson, Ben
dc.contributor.authorGupta, Ravindra
dc.contributor.authorThomson, Emma C
dc.contributor.authorHarrison, Ewan M
dc.contributor.authorLudden, Catherine
dc.contributor.authorReeve, Richard
dc.contributor.authorRambaut, Andrew
dc.contributor.authorCOVID-19 Genomics UK (COG-UK) Consortium
dc.contributor.authorPeacock, Sharon
dc.contributor.authorRobertson, David L
dc.date.accessioned2021-07-02T00:59:35Z
dc.date.available2021-07-02T00:59:35Z
dc.date.issued2021-07
dc.identifier.issn1740-1526
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/324673
dc.description.abstractAlthough most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome are expected to be either deleterious and swiftly purged or relatively neutral, a small proportion will affect functional properties and may alter infectivity, disease severity or interactions with host immunity. The emergence of SARS-CoV-2 in late 2019 was followed by a period of relative evolutionary stasis lasting about 11 months. Since late 2020, however, SARS-CoV-2 evolution has been characterized by the emergence of sets of mutations, in the context of 'variants of concern', that impact virus characteristics, including transmissibility and antigenicity, probably in response to the changing immune profile of the human population. There is emerging evidence of reduced neutralization of some SARS-CoV-2 variants by postvaccination serum; however, a greater understanding of correlates of protection is required to evaluate how this may impact vaccine effectiveness. Nonetheless, manufacturers are preparing platforms for a possible update of vaccine sequences, and it is crucial that surveillance of genetic and antigenic changes in the global virus population is done alongside experiments to elucidate the phenotypic impacts of mutations. In this Review, we summarize the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure, and discuss them in the context of observed mutation frequencies in global sequence datasets.
dc.description.sponsorshipThe COVID-19 Genomics UK (COG-UK) Consortium is supported by funding from the UK Medical Research Council (MRC), part of UK Research and Innovation, the UK National Institute of Health Research and Genome Research Limited, operating as the Wellcome Sanger Institute.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.rightsAll rights reserved
dc.subjectCOVID-19 Genomics UK (COG-UK) Consortium
dc.subjectHumans
dc.subjectAmino Acids
dc.subjectEpitopes
dc.subjectAntigenic Variation
dc.subjectProtein Conformation
dc.subjectMutation
dc.subjectImmune Evasion
dc.subjectSpike Glycoprotein, Coronavirus
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectCOVID-19 Vaccines
dc.titleSARS-CoV-2 variants, spike mutations and immune escape.
dc.typeArticle
prism.endingPage424
prism.issueIdentifier7
prism.publicationDate2021
prism.publicationNameNat Rev Microbiol
prism.startingPage409
prism.volume19
dc.identifier.doi10.17863/CAM.72125
dcterms.dateAccepted2021-04-30
rioxxterms.versionofrecord10.1038/s41579-021-00573-0
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-07
dc.contributor.orcidHarvey, William T [0000-0001-9529-1127]
dc.contributor.orcidCarabelli, Alessandro [0000-0003-3625-4021]
dc.contributor.orcidJackson, Ben [0000-0002-9981-0649]
dc.contributor.orcidGupta, Ravindra [0000-0001-9751-1808]
dc.contributor.orcidReeve, Richard [0000-0003-2589-8091]
dc.contributor.orcidRambaut, Andrew [0000-0003-4337-3707]
dc.contributor.orcidPeacock, Sharon [0000-0002-1718-2782]
dc.contributor.orcidRobertson, David L [0000-0001-6338-0221]
dc.identifier.eissn1740-1534
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMRC (MC_PC_19027)
pubs.funder-project-idMRC (via Imperial College London) (MR/W005611/1)
cam.issuedOnline2021-06-01
cam.orpheus.successMon Jul 05 07:30:29 BST 2021 - Embargo updated
rioxxterms.freetoread.startdate2021-12-01


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record